Specialist-Directed Treatment and Nutritional Support
At a Glance
Autoimmune enteropathy treatment is individualized and specialist-directed: steroids often control active inflammation, while immune-suppressing medicines or biologics may maintain remission. Severe malabsorption can require total parenteral nutrition (TPN) and close safety monitoring.
Treating autoimmune enteropathy (AIE) is a two-step process: first, doctors must “put out the fire” of active inflammation; second, they must prevent that fire from returning while supporting the body’s nutritional needs. Because AIE is so rare, there is no single “gold standard” treatment protocol or high-quality comparative trial. Treatment strategies rely on individualized, specialist-directed options, often involving off-label use of medications supported by limited case series [1][2].
Initial Attack: Induction Therapy
The first goal of treatment is to stop the immune system’s immediate attack on the small intestine. This is known as induction therapy and, after excluding infection or medication injury, often begins with glucocorticoids (steroids) [1].
- Systemic Steroids: Medications like prednisone or intravenous methylprednisolone are often used first. They work quickly to dampen the immune response across the entire body [3]. In small adult retrospective cohorts, about 62% to 87.5% of patients show a clinical response to steroids. However, symptom response and tissue healing happen on different timelines, and a lack of immediate response is not always decisive [1][4].
- Open-Capsule Budesonide: Budesonide is a steroid that primarily works locally in the gut, which helps reduce body-wide side effects [5]. While standard capsules release in the lower digestive tract, AIE affects the upper small intestine. In one small study, 85% of AIE patients responded when doctors recommended an “open-capsule” technique [5]. CRITICAL SAFETY WARNING: This is an off-label, specialist-directed approach. Opening a capsule alters a modified-release formulation and changes exposure. Never open, crush, or change a formulation without explicit instruction from your prescriber and pharmacist.
Staying in Remission: Maintenance Therapy
Steroids are excellent at stopping an attack, but they can cause significant side effects if used long-term—including bone thinning, high blood sugar, and increased infection risk [6]. To avoid this, doctors use steroid-sparing agents for long-term maintenance therapy [1].
Commonly used maintenance medications require rigorous safety monitoring:
- Tacrolimus and Cyclosporine: These are calcineurin inhibitors that prevent immune cells from becoming overactive. They require regular blood tests to ensure the drug level is safe and to monitor kidney function and blood pressure [7][8].
- Azathioprine: This drug slows down the production of immune cells but commonly requires consideration of TPMT/NUDT15 genetic status and strict blood-count/liver monitoring [9].
- Mycophenolate Mofetil (MMF): Carries important pregnancy and infection risks [10].
- Sirolimus: Sometimes used as a second-line option for patients who do not respond to other immunosuppressants [2].
Vaccination Note: Discuss an individualized vaccine plan with your team. Live vaccines may be unsafe during significant immunosuppression and require specialist approval.
Biologics: The “Step-Up” Options
If traditional immunosuppressants are not enough, doctors may try biologics—engineered proteins that target very specific parts of the immune system. The evidence for biologics in AIE is limited to case series and results can be mixed [4].
- Infliximab: An anti-TNF drug. Some AIE patients achieve remission with it, while others may experience an initial response followed by a relapse [11][12].
- Vedolizumab: This is a gut-selective biologic. Case reports show it can lead to symptomatic and histologic (tissue-level) improvement in some AIE patients, though it is not effective for everyone [13][14].
Life-Sustaining Support: TPN and Nutrition
Because AIE causes severe malabsorption, the body often cannot take in enough calories or fluids to survive. Total Parenteral Nutrition (TPN) is frequently required—in one small specialty center cohort, 62% of adult AIE patients needed this support [4].
TPN is a method of bypassing the digestive system entirely by delivering a specialized cocktail of fluids, electrolytes, vitamins, and minerals directly into a large vein through a central line [15].
- The Role of Gut Rest: Enteral/oral feeding is generally used whenever feasible. In severe intestinal failure, an individualized, short-term decision for “gut rest” (consuming nothing by mouth) may be made. However, TPN supports nutrition when oral intake is inadequate; it does not automatically heal the bowel [16].
- TPN Risks: TPN itself carries major risks, including life-threatening central-line infections, thrombosis (blood clots), severe electrolyte swings (refeeding syndrome), and liver complications.
- Trophic Feeding: As safe, doctors may introduce tiny amounts of “trophic” (nourishing) feeds. These are not meant to provide full calories but rather to “wake up” the intestine while the patient is primarily supported by TPN [17].
Managing AIE requires constant monitoring. Success is measured not just by the cessation of diarrhea, but by mucosal healing and the patient’s ability to maintain a healthy weight [15][18].
Common questions in this guide
What treatment is usually started first for autoimmune enteropathy?
Can I open a budesonide capsule to treat autoimmune enteropathy?
Which medicines can help keep autoimmune enteropathy in remission?
When might biologic treatment be considered for autoimmune enteropathy?
Why might someone with autoimmune enteropathy need TPN?
What monitoring and vaccine precautions are important during treatment?
Get notified when new evidence is published on Primary autoimmune enteropathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: Experience from Peking Union Medical College Hospital.
Li MH, Ruan GC, Zhou WX, et al.
World journal of gastroenterology 2024; (30(19)):2523-2537 doi:10.3748/wjg.v30.i19.2523.
PMID: 38817655 - 2
Advances and challenges in diagnosing and managing adult autoimmune enteropathy.
Christodoulidis G, Agko SE, Kouliou MN, et al.
World journal of gastroenterology 2025; (31(2)):99118 doi:10.3748/wjg.v31.i2.99118.
PMID: 39811507 - 3
Adult autoimmune enteropathy in autoimmune hepatitis patient. Case report and literature review.
Iaquinto G, Panico L, Luongo G, et al.
Clinics and research in hepatology and gastroenterology 2021; (45(3)):101673 doi:10.1016/j.clinre.2021.101673.
PMID: 33744411 - 4
Adult-Onset Autoimmune Enteropathy in an European Tertiary Referral Center.
van Wanrooij RLJ, Neefjes-Borst EA, Bontkes HJ, et al.
Clinical and translational gastroenterology 2021; (12(8)):e00387 doi:10.14309/ctg.0000000000000387.
PMID: 34333499 - 5
Features of Adult Autoimmune Enteropathy Compared With Refractory Celiac Disease.
Sharma A, Choung RS, Wang XJ, et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2018; (16(6)):877-883.e1 doi:10.1016/j.cgh.2017.12.044.
PMID: 29307846 - 6
Long-term efficacy and safety of different corticosteroid courses plus mycophenolate mofetil for autoimmune encephalitis with neuronal surface antibodies without tumor.
Li D, Huang T, Zhang F, et al.
Frontiers in immunology 2023; (14()):1195172 doi:10.3389/fimmu.2023.1195172.
PMID: 37503335 - 7
Efficacy of tacrolimus as long-term immunotherapy for neuronal surface antibody-mediated autoimmune encephalitis.
Liu C, Ji S, Gao H, et al.
Therapeutic advances in chronic disease 2022; (13()):20406223211063055 doi:10.1177/20406223211063055.
PMID: 35035868 - 8
Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management.
Abboud H, Probasco J, Irani SR, et al.
Journal of neurology, neurosurgery, and psychiatry 2021; doi:10.1136/jnnp-2020-325302.
PMID: 33649021 - 9
Thymoma-associated autoimmune enteropathy with colonic stricture: a diagnostic and histological challenge.
Pieplenbosch B, de Leijer JH, van Dop WA, et al.
Clinical journal of gastroenterology 2022; (15(1)):112-116 doi:10.1007/s12328-021-01531-2.
PMID: 34676508 - 10
Mycophenolate mofetil in paediatric autoimmune or immune-mediated diseases of the central nervous system: clinical experience and recommendations.
Nosadini M, Gadian J, Lim M, et al.
Developmental medicine and child neurology 2019; (61(4)):458-468 doi:10.1111/dmcn.14020.
PMID: 30221751 - 11
A man in his fifties with chronic diarrhoea and weight loss.
Sarna VK, Lunding J, Løberg EM, Solberg IC
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 2020; (140(11)) doi:10.4045/tidsskr.19.0812.
PMID: 32815334 - 12
Seronegative Adult Autoimmune Enteropathy in a Male Traveler.
McCabe P, Alli-Akintade L, Stondell J
ACG case reports journal 2017; (4()):e19 doi:10.14309/crj.2017.19.
PMID: 28184376 - 13
New Treatment Option for Autoimmune Enteropathy: A Rare Case of Intractable Diarrhea Treated with Vedolizumab.
Robbins G, Tracht J, Davis D, Iskandar H
ACG case reports journal 2018; (5()):e92 doi:10.14309/crj.2018.92.
PMID: 30775395 - 14
Treatment of Autoimmune Enteropathy With Vedolizumab.
Alleyasin T, Wilder E, Reidel W, et al.
ACG case reports journal 2025; (12(6)):e01716 doi:10.14309/crj.0000000000001716.
PMID: 40452653 - 15
Isolated Intestine Transplantation for Autoimmune Enteropathy: A Case Report.
Soma D, Saxena R, Arman ME, et al.
Transplantation proceedings 2020; (52(9)):2835-2838 doi:10.1016/j.transproceed.2020.08.007.
PMID: 32854966 - 16
Autoimmune Enteropathy: An Updated Review with Special Focus on Stem Cell Transplant Therapy.
Ahmed Z, Imdad A, Connelly JA, Acra S
Digestive diseases and sciences 2019; (64(3)):643-654 doi:10.1007/s10620-018-5364-1.
PMID: 30415406 - 17
Gastrointestinal dysmotility in the critically ill: a role for nutrition.
Weimann A, Felbinger TW
Current opinion in clinical nutrition and metabolic care 2016; (19(5)):353-359 doi:10.1097/MCO.0000000000000300.
PMID: 27341126 - 18
Comprehensive insights into pathogenesis, diagnosis, treatment, and prognosis in adult autoimmune enteropathy.
Li M, Xu T, Ruan G, et al.
Orphanet journal of rare diseases 2025; (20(1)):208 doi:10.1186/s13023-025-03731-2.
PMID: 40317016
This page is for informational purposes only and does not constitute medical advice. Treatment decisions, including medication formulation changes and TPN, should be made with your specialist, prescriber, pharmacist, and nutrition team.